NeurAxis (NRXS) Stock Overview
A medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
NRXS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
NeurAxis, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.62 |
| 52 Week High | US$7.97 |
| 52 Week Low | US$1.33 |
| Beta | 2.49 |
| 1 Month Change | 42.43% |
| 3 Month Change | 136.65% |
| 1 Year Change | 229.87% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 27.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| NRXS | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 11.1% | -0.3% | -1.9% |
| 1Y | 229.9% | -11.2% | 14.9% |
Return vs Industry: NRXS exceeded the US Medical Equipment industry which returned -10.9% over the past year.
Return vs Market: NRXS exceeded the US Market which returned 16.5% over the past year.
Price Volatility
| NRXS volatility | |
|---|---|
| NRXS Average Weekly Movement | 13.1% |
| Medical Equipment Industry Average Movement | 7.8% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: NRXS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NRXS's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 21 | Brian Carrico | neuraxis.com |
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal expulsion device, a screening tool that helps to detects evacuation disorders.
NeurAxis, Inc. Fundamentals Summary
| NRXS fundamental statistics | |
|---|---|
| Market cap | US$81.17m |
| Earnings (TTM) | -US$8.62m |
| Revenue (TTM) | US$3.57m |
Is NRXS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NRXS income statement (TTM) | |
|---|---|
| Revenue | US$3.57m |
| Cost of Revenue | US$562.92k |
| Gross Profit | US$3.01m |
| Other Expenses | US$11.62m |
| Earnings | -US$8.62m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.81 |
| Gross Margin | 84.23% |
| Net Profit Margin | -241.37% |
| Debt/Equity Ratio | 4.4% |
How did NRXS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/21 23:24 |
| End of Day Share Price | 2026/03/20 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NeurAxis, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Karen Sterling | Kingswood Capital |
| Casey Ryan | WestPark Capital, Inc. |